Liso-cel

BIOLOGICAL4 trials

Conditions

DLBCL - Diffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaIndolent B-Cell Non-Hodgkin LymphomaLeukemia, Lymphocytic, Chronic, B-CellLymphomaMediastinal Large B-cell LymphomaRefractory Non-Hodgkin Lymphoma

Phase 1

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Active, not recruitingNCT05621096

University of NebraskaDLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma, High-grade B-cell Lymphoma +4

Start: 2023-03-21End: 2027-09-30Target: 33Updated: 2025-09-25

Phase 2

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

RecruitingNCT07015242

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLymphoma

Start: 2025-11-06End: 2028-12-10Target: 65Updated: 2026-09-01

Phase 3

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

WithdrawnNCT06205290

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2024-01-16End: 2031-10-13Updated: 2024-04-02

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

WithdrawnNCT06313996

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyRelapsed or Refractory Follicular Lymphoma

Start: 2024-03-29End: 2031-10-16Updated: 2026-03-18

Related Papers

Lisocabtagene maraleucel (liso-cel) as first-line (1L) therapy for transplant-ineligible patients (pt) with primary central nervous system lymphoma (PCNSL): The CAROLYN study.